The intravitreal use of corticosteroids

References

• Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch. Ophthalmol.92(2), 149–154 (1974).
   PubMed Web of Science ®Google Scholar
• Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol.90(6), 810–816 (1980).
   PubMed Web of Science ®Google Scholar
• McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am. J. Ophthalmol.91(6), 785–788 (1981).
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol.103(5), 708–711 (1985).
   PubMed Web of Science ®Google Scholar
• Hatchell DL, McAdoo T, Sheta S, King RT 3rd, Bartolomé JV. Quantification of cellular proliferation in experimental proliferative vitreoretinopathy. Arch. Ophthalmol.106(5), 669–672 (1988).
   PubMedGoogle Scholar
• Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol.231(1), 34–40 (1993).
   PubMed Web of Science ®Google Scholar
• Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. N. Z. J. Ophthalmol.23(4), 293–298 (1995).
   PubMedGoogle Scholar
• Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust. N. Z. J. Ophthalmol.27(6), 431–432 (1999).
   PubMedGoogle Scholar
• Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina20(3), 244–250 (2000).
   PubMed Web of Science ®Google Scholar
• Sommer A, Veraart J, Neumann M, Kessels A. Evaluation of the vasoconstrictive effect of topical steroids by laser-Doppler-perfusion-imaging. Acta Derm. Venereol.78(1), 15–18 (1998).
   PubMed Web of Science ®Google Scholar
• Adler RA, Naumann SA, Mansouri A, Krieg RJ Jr, Latta K, Sanders KM. Anti-proliferative effects of deflazacort on Nb2 cells as quantitated by formazan production. Life Sci.55(23), 1823–1831 (1994).
   PubMed Web of Science ®Google Scholar
• Felinski EA, Cox AE, Phillips BE, Antonetti DA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp. Eye Res.86(6), 867–878 (2008).
   PubMed Web of Science ®Google Scholar
• Wenzel A, Grimm C, Seeliger MW et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest. Ophthalmol. Vis. Sci.42(7), 1653–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Argenti D, Jensen BK, Hensel K et al. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol.40(7), 770–780 (2000).
   PubMed Web of Science ®Google Scholar
• Karacorlu M, Ozdemir H, Senturk F, Arf Karacorlu S, Uysal O. Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur. J. Ophthalmol.18(4), 601–608 (2008).
   PubMed Web of Science ®Google Scholar
• Wickremasinghe SS, Rogers SL, Gillies MC, Zhu M, Wong TY. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest. Ophthalmol. Vis. Sci.49(11), 4707–4711 (2008).
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am. J. Ophthalmol.137(3), 560–562 (2004).
   PubMed Web of Science ®Google Scholar
• Mason JO 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina24(6), 900–904 (2004).
   PubMed Web of Science ®Google Scholar
• Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrecomised eye. Br. J. Ophthalmol.90(6), 705–708 (2006).
   PubMed Web of Science ®Google Scholar
• Chang YS, Wu CL, Tseng SH, Kuo PY, Tseng SY. In vitro benzyl alcohol cytotoxicity: implications for intravitreal use of triamcinolone acetonide. Exp. Eye Res.86(6), 942–950 (2008).
   PubMed Web of Science ®Google Scholar
• Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone’s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch. Clin. Exp. Ophthalmol.245(6), 817–824 (2007).
   PubMed Web of Science ®Google Scholar
• Morrison VL, Koh HJ, Cheng L, Bessho K, Davidson MC, Freeman WR. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina26(3), 339–344 (2006).
   PubMed Web of Science ®Google Scholar
• Stepien KE, Eaton AM, Jaffe GJ, Davis JL, Raja J, Feuer W. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina29(2), 207–213 (2009).
   PubMed Web of Science ®Google Scholar
• Bitter C, Suter K, Figueiredo V, Pruente C, Hatz K, Surber C. Preservative-free triamcinolone acetonide suspension developed for intravitreal injection. J. Ocul. Pharmacol. Ther.24(1), 62–69 (2008).
   PubMed Web of Science ®Google Scholar
• Salvolini E, Neri P, Orciani M, Di Primio R, Giovannini A. Intravitreal micronized triamcinolone versus triamcinolone acetonide: a clinical and morphological comparative study. Int. J. Immunopathol. Pharmacol.21(1), 181–188 (2008).
   PubMed Web of Science ®Google Scholar
• Bollinger KE, Smith SD. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr. Opin. Ophthalmol.20(2), 99–103 (2009).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol.125(3), 309–317 (2007).
   PubMed Web of Science ®Google Scholar
• Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina29(1), 46–51 (2009).
   PubMed Web of Science ®Google Scholar
• Bresnick GH. Diabetic macular edema. A review. Ophthalmology93(7), 989–997 (1986).
   PubMed Web of Science ®Google Scholar
• No authors listed. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch. Ophthalmol.103(12), 1796–1806 (1985).
   PubMed Web of Science ®Google Scholar
• Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci.44(3), 1192–1201 (2003).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am. J. Ophthalmol.132(3), 425–427 (2001).
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology109(5), 920–927 (2002).
   PubMed Web of Science ®Google Scholar
• Faghihi H, Roohipoor R, Mohammadi SF et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur. J. Ophthalmol.18(6), 941–948 (2008).
   PubMed Web of Science ®Google Scholar
• Maia OO Jr, Takahashi BS, Costa RA, Scott IU, Takahashi WY. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am. J. Ophthalmol.147(2), 291–297 (2009).
   PubMed Web of Science ®Google Scholar
• Faghihi H, Taheri A, Farahvash MS, Esfahani MR, Rajabi MT. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina28(9), 1241–1246 (2008).
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology115(9), 1447–1459 (2008).
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol.127(3), 245–251 (2009).
   PubMed Web of Science ®Google Scholar
• Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst. Rev.1, CD005656 (2008).
   Google Scholar
• Pearson P, Levy B, Comstock T. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Invest. Ophthalmol. Vis. Sci.47, E-Abstract 5442 (2006).
   PubMedGoogle Scholar
• No authors listed. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology102(10), 1425–1433 (1995).
   PubMed Web of Science ®Google Scholar
• Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am. J. Ophthalmol.136(3), 419–425 (2003).
   PubMed Web of Science ®Google Scholar
• Ip MS, Gottlieb JL, Kahana A et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch. Ophthalmol.122(8), 1131–1136 (2004).
   PubMedGoogle Scholar
• Wang L, Song H. Effects of repeated injection of intravitreal triamcinolone on macular oedema in central retinal vein occlusion. Acta Ophthalmol.87(3), 285–289 (2009).
   PubMed Web of Science ®Google Scholar
• Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye23(12), 2215–2222 (2009).
   PubMed Web of Science ®Google Scholar
• Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst. Rev.1, CD007324 (2009).
   Google Scholar
• Scott IU, VanVeldhuisen PC, Oden NL et al. SCORE study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology116(3), 504–512 (2009).
   PubMed Web of Science ®Google Scholar
• Ip MS, Scott IU, VanVeldhusien PC. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Cotricosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch. Ophthalmol.127(9), 1101–1114 (2009).
   PubMed Web of Science ®Google Scholar
• No authors listed. Argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol.98, 271–282 (1984).
   PubMed Web of Science ®Google Scholar
• Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H. Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol.246(12), 1671–1676 (2008).
   PubMed Web of Science ®Google Scholar
• Scott IU, VanVeldhuisen PC, Oden NL et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch. Ophthalmol.127(9), 1115–1128 (2009).
   PubMed Web of Science ®Google Scholar
• Klein R, Peto T, Bird A, Vannerwkirk MR. The epidemiology of age-related macular degeneration. Am. J. Ophthalmol.137, 486–495 (2004).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol.121(5), 667–673 (2003).
   PubMed Web of Science ®Google Scholar
• Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. N. Z. J. Ophthalmol.23(4), 293–298 (1995).
   PubMedGoogle Scholar
• Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye19(2), 163–170 (2005).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology112(2), 301–304 (2005).
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology113(1), 14–22 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology114(12), 2183–2189 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Weigert G, Michels S, Sacu S et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br. J. Ophthalmol.92(3), 356–360 (2008).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Ihloff AK, Harder B et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res.41(1), 21–27 (2009).
   PubMed Web of Science ®Google Scholar
• Sacu S, Michels S, Prager F et al. Randomised clinical trial of intravitreal avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye23(12), 2223–2227 (2009).
   PubMed Web of Science ®Google Scholar
• Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology112(11), 1916.e1–e7 (2005).
   PubMed Web of Science ®Google Scholar
• Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul. Immunol. Inflamm.13(2–3), 205–212 (2005).
   PubMed Web of Science ®Google Scholar
• Dong Z, Namba K, Kitaichi N, Goda C, Kitamura M, Ohno S. Efficacy and complications of intravitreal injection of triamcinolone acetonide for refractory cystoid macular edema associated with intraocular inflammation. Jpn J. Ophthalmol.52(5), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur. J. Ophthalmol.18(3), 429–434 (2008).
   PubMed Web of Science ®Google Scholar
• Sallam A, Comer RM, Chang JH et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch. Ophthalmol.126(2), 200–205 (2008).
   PubMed Web of Science ®Google Scholar
• Weiss K, Steinbrugger I, Weger M et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye23(9), 1812–1818 (2009).
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol.126(9), 1191–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvin-Grass syndrome. Am. J. Ophthalmol.147(6), 1048–1054 (2009).
   PubMed Web of Science ®Google Scholar
• Morrison VL, Kozak I, LaBree LD et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology114(2), 334–339 (2007).
   PubMed Web of Science ®Google Scholar
• Sorensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol. Scand.83(1), 67–70 (2005).
   PubMedGoogle Scholar
• Boscia F, Furino C, Dammacco R et al. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur. J. Ophthalmol.15(1), 89–95 (2005).
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Garcia-Amaris RA, Roca JA. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology116(8), 1481–1487 (2009).
   PubMed Web of Science ®Google Scholar
• Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog. Retin. Eye Res.18, 629–667 (1999).
   PubMed Web of Science ®Google Scholar
• Im L, Allingham RR, Singh I, Stinnett S, Fekrat S. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. J. Glaucoma17(2), 128–132 (2008).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal J, Agrawal TP. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol.138(4), 679–680 (2004).
   PubMed Web of Science ®Google Scholar
• Breusegem C, Vandewalle E, Van Calster J, Stalmans I, Zeyen T. Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection. Invest. Ophthalmol. Vis. Sci.50(2), 573–576 (2009).
   PubMed Web of Science ®Google Scholar
• Yildirim N, Sahin A, Erol N, Kara S, Uslu S, Topbas S. The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection. J. Glaucoma.17(4), 253–256 (2008).
   PubMed Web of Science ®Google Scholar
• Oliver A, Gao H, WuDunn D, Peracha MO, Cantor LB. Intravitreal triamcinolone injection in patients with surgically controlled glaucoma. Arch. Ophthalmol.124(12), 1788–1790 (2006).
   PubMedGoogle Scholar
• Lau LI, Chen KC, Lee FL et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am. J. Ophthalmol.146(4), 573–578 (2008).
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol.136(5), 791–796 (2003).
   PubMed Web of Science ®Google Scholar
• Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch. Ophthalmol.121(2), 271–273 (2003).
   PubMed Web of Science ®Google Scholar
• Bucher RS, Johnson MW. Microbiologic studies of multiple-dose containers of triamcinolone acetonide and lidocaine hydrochloride. Retina25(3), 269–271 (2005).
   PubMed Web of Science ®Google Scholar
• Song JH, Hong YT, Kwon OW. Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection. Graefes Arch. Clin. Exp. Ophthalmol.246(12), 1775–1778 (2008).
   PubMed Web of Science ®Google Scholar
• Park YS, Byeon SH. Cytomegalovirus retinitis after intravitreous triamcinolone injection in a patient with central retinal vein occlusion. Korean J. Ophthalmol.22(2), 143–144 (2008).
   PubMedGoogle Scholar
• Sekiryu T, Iida T, Kaneko H, Saito M. Cytomegalovirus retinitis after intravitreal triamcinolone acetonide in an immunocompetent patient. Jpn J. Ophthalmol.52(5), 414–416 (2008).
   PubMed Web of Science ®Google Scholar
• Delyfer MN, Rougier MB, Hubschman JP, Aouizérate F, Korobelnik JF. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol. Scand.85(6), 681–683 (2007).
   PubMedGoogle Scholar
• Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am. J. Ophthalmol.140(6), 1141–1143 (2005).
   PubMed Web of Science ®Google Scholar
• Jonisch J, Lai JC, Deramo VA, Flug AJ, Fastenberg DM. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br. J. Ophthalmol.92(8), 1051–1054 (2008).
   PubMed Web of Science ®Google Scholar
• Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul. Immunol. Inflamm.13(4), 295–300 (2005).
   PubMed Web of Science ®Google Scholar
• Sakalar YB, Unlu K, Keklikci U, Caca I, Senol BB. Persistent triamcinolone acetonide particles on the posterior lens capsule after intravitreal injection. Ann. Ophthalmol. (Skokie)40(3–4), 190–192 (2008).
   PubMedGoogle Scholar
• Viestenz A, Küchle M, Behrens-Baumann W. Globe explosion due to intravitreal injection. Klin. Monbl. Augenheilkd.225(12), 1087–1090 (2008).
   PubMed Web of Science ®Google Scholar
• Lo Giudice G, De Belvis V, Piermarocchi S, Galan A, Prosdocimo G. Acute visual loss and chorioretinal infarction after photodynamic therapy combined with intravitreal triamcinolone. Eur. J. Ophthalmol.18(4), 652–655 (2008).
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker RJ, Abdelghani WM, Schuman JS. Filtering bleb rupture after intravitreal triamcinolone acetonide injection. Ophthalmic Surg. Lasers Imaging39(3), 232–233 (2008).
   PubMedGoogle Scholar
• Blaha GR, Wertz FD 3rd, Marx JL. Profound choroidal hypoperfusion after combined photodynamic therapy and intravitreal triamcinolone acetonide. Ophthalmic Surg. Lasers Imaging39(1), 6–11 (2008).
   PubMedGoogle Scholar